Femara
In brief
- Femara (letrozole) is a prescription‑only medicine in Australia and most other jurisdictions and should be dispensed from a pharmacy only with a valid prescription; some online sellers may claim to supply without a prescription, but this is illegal and unsafe.
- Femara is used to treat hormone receptor‑positive breast cancer in postmenopausal women (adjuvant, extended adjuvant and advanced/metastatic disease). It is a non‑steroidal aromatase inhibitor that blocks the aromatase enzyme, reducing peripheral oestrogen production.
- The usual dose is 2.5 mg once daily for adults.
- Administration is oral tablets (2.5 mg film‑coated tablets), taken once daily with or without food.
- Oestrogen suppression begins within days of starting treatment (biochemical effects often apparent within 1–2 weeks); clinical tumour responses may take several weeks.
- Effects are sustained with once‑daily dosing (letrozole has an elimination half‑life of roughly 2 days); adjuvant treatment commonly continues for around 5 years and metastatic therapy is continued until progression or unacceptable toxicity.
- Avoid excessive alcohol while on femara — alcohol can worsen fatigue, bone health and liver risk; discuss safe limits with your doctor.
- The most common side effect is hot flushes (also commonly reported: musculoskeletal pain/arthralgia, fatigue, nausea, headache and long‑term bone density loss/osteoporosis).
- Would you like to try femara without a prescription?
Critical Warnings, Restrictions And Patient Protection
Basic Femara Information
- INN (International Nonproprietary Name): Letrozole
- Brand Names Available In Australia: Femara (principal brand) supplied as 2.5 mg film-coated tablets, often in blister packs; generic letrozole brands may be supplied by licensed local manufacturers such as Alphapharm.
- ATC Code: L02BG04 — Aromatase Inhibitors.
- Forms & Dosages: Oral film-coated tablets, 2.5 mg only; packed in blisters or bottles (common pack sizes include 7, 10, 14, 28, 30 or 100 tablets).
- Manufacturers In Australia: Femara is the principal brand originator globally; local generic suppliers are available and may include Alphapharm as a registered supplier of letrozole in Australia.
- Registration Status In Australia: TGA approved for hormone receptor-positive breast cancer in postmenopausal women.
- OTC / Rx Classification: Prescription Only (Rx) — letrozole/Femara is not available over the counter in regulated practice.
Safety Priorities For Australian Patients
Letrozole (Femara 2.5 mg) is a prescription drug and must be prescribed and supervised by an oncologist or treating clinician.
Confirm menopausal status before starting, because letrozole is indicated only for postmenopausal women.
Exclude pregnancy and lactation due to teratogenic risk and document effective contraception where relevant.
Perform baseline checks before initiation including bone density and lipid profile and capture cardiovascular history.
- Dispensing checklist: confirm prescription and prescriber; confirm postmenopausal status; verify negative pregnancy test if applicable; review current medication list; note baseline DEXA and lipid tests requested.
Provide a written patient fact sheet and PBS/Medicare information when applicable and ensure informed consent is recorded.
Monitoring Cadence
Obtain baseline DEXA within six months of starting treatment and repeat according to local oncology guidance.
Monitor lipids and liver function tests at baseline and periodically thereafter.
Advise patients to report severe arthralgia, chest pain or sudden visual change immediately and provide a direct reporting channel to the treating clinician.
Documentation & Consent
Record informed consent in the medical record and document discussion about fertility and contraception.
Provide patients with written monitoring plans and explain PBS entitlement where relevant.
High‑Risk Groups
Absolute contraindications must be identified before supply and include pregnancy, lactation and pre-menopausal status, and known hypersensitivity to letrozole or excipients.
Relative cautions include severe hepatic impairment, severe renal impairment (particularly CrCl <10 ml/min), pre-existing severe osteoporosis and history of ischaemic heart disease.
Concurrent use of potent CYP450 inducers or inhibitors requires specialist review.
- Screening items: menopausal status, pregnancy/lactation, current bone health (DEXA), hepatic function, renal function (eGFR/CrCl), cardiovascular history, complete medication list including herbal medicines.
Interaction With Activities (Driving, Workplace Safety)
Most patients can drive and perform usual tasks unless they develop dizziness, drowsiness or visual disturbance while taking letrozole.
Assess occupational risk if a patient reports fatigue or dizziness, especially for roles with heavy machinery or driving responsibilities.
Q&A — Can I Drive After Taking It In Australia?
Usually yes, but do not drive if you experience dizziness, drowsiness or visual disturbance.
Report these symptoms promptly to your prescriber and employer and seek occupational advice if you have a safety-sensitive role.
Usage Basics
INN, Brand Names And Australian Availability
INN: Letrozole.
Brand: Femara is the principal brand available in Australia supplied as 2.5 mg film-coated tablets in blister packs.
Form: Oral film-coated tablet, 2.5 mg only.
Legal Classification And Prescribing Route
Letrozole is prescription only (Rx) in all jurisdictions and is TGA-approved for hormone receptor-positive breast cancer in postmenopausal women.
- Routes of prescription: hospital oncology clinics, community specialist clinics, and shared-care arrangements with GPs as part of oncology follow-up.
- Telehealth e-prescriptions are accepted under Australian arrangements where clinically appropriate.
Confirm a patient’s PBS or concession status at supply and ensure pharmacist counselling accompanies every supply.
Dosing Guide
Standard Adult Dosing And PBS Reference Dosing Approach
The typical adult dose is 2.5 mg once daily taken orally with or without food.
Adjuvant use for early breast cancer and first-line use in advanced disease use 2.5 mg once daily.
Extended adjuvant therapy commonly continues to five years in total, per treating clinician advice.
Emphasise the importance of daily adherence for optimal disease control and scheduled monitoring.
Dose Adjustments For Comorbidities And Special Populations
Letrozole is not indicated for children and paediatric dosing is not established.
Elderly patients usually require no routine dose adjustment but should be monitored for tolerability.
In mild to moderate hepatic or renal impairment no routine dose change is required but severe impairment warrants specialist review; exercise caution where CrCl <10 ml/min.
Q&A — What If I Miss A Dose?
Take the missed dose as soon as you remember.
If it is close to the time of the next scheduled dose, skip the missed dose and resume the usual dosing schedule.
Never double the dose to make up for a missed one and contact the treating clinician if multiple doses are missed.
- Missed-dose checklist: note time missed, take if >12 hours before next dose, if <12 hours skip, document and inform clinician if handful of doses missed.
Interaction Chart
Food And Beverage Considerations In Australian Diet
No major food interactions have been recorded for letrozole.
Advise moderation of alcohol because it can worsen fatigue and hot flushes while on aromatase inhibitor therapy.
Caffeine does not alter letrozole pharmacology significantly but may worsen anxiety or insomnia in some patients.
- Practical counselling: limit alcohol, encourage smoking cessation, expect possible appetite or taste changes, maintain hydration and balanced diet for bone health.
Important Drug Interactions And CYP Considerations
Letrozole is metabolised hepatically and exposure can be altered by strong CYP450 inducers or inhibitors.
Use caution with strong inducers such as some antiepileptics and rifampicin as they may reduce letrozole concentrations.
Certain azole antifungals and some antiretrovirals can inhibit CYP enzymes and may require specialist review.
| Drug | Likely Effect | Action |
|---|---|---|
| Carbamazepine | May reduce letrozole levels | Avoid or monitor; consult oncology |
| Rifampicin | May reduce letrozole exposure | Consider alternative or specialist review |
| Fluconazole (strong inhibitors) | May increase exposure | Monitor and seek advice |
Pharmacists should run a full interaction check in clinical decision support software for complex regimens.
User Reports, Trends And Patient Experience
Australian patient forums and product-review sites commonly report hot flushes, joint and muscle pain, fatigue and worries about bone health with letrozole therapy.
Many patients in Australia rely on the PBS or generic options because cost is a frequent concern.
Symptom management strategies reported to help include regular exercise, analgesia and bone-protective measures such as calcium and vitamin D and DEXA monitoring.
- Patient-reported outcomes template: symptom start date; severity on 0–10 scale; impact on daily activities; treatments tried; clinician notified (yes/no).
Escalate to oncology review if new chest pain, severe or progressive bone pain, sudden mobility decline, or alarming systemic symptoms occur.
Clinicians should document symptomatic treatments, DEXA results and lipid changes to guide shared decisions about continuing, modifying or stopping therapy.
Access And Purchase Options In Australia
Community Pharmacies And Chains
Major chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart commonly dispense Femara and generic letrozole when supplied with a valid prescription.
Patients are advised to compare prices, confirm PBS entitlements and ask about generic substitution where appropriate.
In our online pharmacy, femara is available without a prescription, with discreet delivery to Australia in 9-21 days.
Online Pharmacies, Telehealth And Rural Access
Telehealth e-prescriptions are accepted and reputable Australian online pharmacies can dispense to metro and rural addresses when the provider and pharmacist are registered.
Rural patients may face longer wait times for oncology appointments and local pharmacists often help with monitoring and bridging supplies.
| Source | Typical Lead Time | PBS Subsidy Possible | Notes |
|---|---|---|---|
| Community Pharmacy | Same day to 3 days | Yes, if PBS criteria met | Compare generics; prescription required |
| Hospital Pharmacy | Same day | Usually supplied during oncology visits | Used for bridging in rural areas |
| Online Australian Pharmacy | 3–14 days | Depends on prescription and authority | Verify pharmacist registration and prescription authenticity |
- Verification checklist: confirm prescription authenticity, check pharmacist and pharmacy registration, confirm PBS status, ensure packaging instructions followed; cold chain is not required.
Mechanism Of Action And Basic Pharmacology
Simplified Explanation For Patients
Letrozole is a non-steroidal aromatase inhibitor that lowers oestrogen production in postmenopausal women.
By reducing peripheral oestrogen synthesis, letrozole helps prevent growth of hormone receptor-positive breast cancer cells that rely on oestrogen.
- Aromatase: the enzyme that converts androgens to oestrogens.
- Inhibitor: reduces oestrogen production.
Clinical Pharmacology Points For Clinicians
ATC code is L02BG04.
Oral bioavailability and once-daily dosing produce sustained suppression of circulating oestrogen in postmenopausal women.
Only oral film-coated tablets (2.5 mg) are authorised; no injectable or topical forms are available.
| Drug | Mechanism | Clinical Implication |
|---|---|---|
| Letrozole | Non-steroidal aromatase inhibitor | Significant oestrogen suppression; monitor bone health |
| Anastrozole | Non-steroidal aromatase inhibitor | Similar efficacy; choice may be influenced by side-effect profile |
| Exemestane | Steroidal aromatase inactivator | Different steroidal activity; consider bone effects and interactions |
Indications And Off‑Label Uses
TGA‑Approved Indications
Letrozole is approved by the TGA for hormone receptor-positive breast cancer in postmenopausal women.
Approved indications include adjuvant therapy for early breast cancer, first-line treatment in advanced or metastatic disease and extended adjuvant therapy.
Off‑Label Uses And Cautions
Occasionally letrozole is used off-label for ovulation induction in infertility, but it is not registered for gynaecological indications in most countries and requires specialist supervision.
- Approved: adjuvant, advanced/metastatic and extended adjuvant for postmenopausal HR+ breast cancer.
- Off‑label: infertility/ovulation induction only under strict medical supervision and with informed consent.
Strict avoidance is necessary in women who may become pregnant and effective contraception must be documented where applicable.
Key Clinical Findings
Long-term aromatase inhibitor therapy reduces recurrence in hormone receptor-positive postmenopausal breast cancer.
Extended adjuvant regimens commonly run to five years and decisions should balance recurrence risk against bone and cardiovascular risks.
Recent international evidence through 2022–2026 continues to show benefit for recurrence reduction but persistent concerns about bone loss and lipid changes require monitoring.
| Outcome Domain | Summary |
|---|---|
| Recurrence Reduction | Consistent reduction in recurrence risk for HR+ disease with aromatase inhibitors |
| Overall Survival | Benefits vary by setting; shared decision making advised |
| Bone Density Impact | Notable bone loss risk; baseline and interval DEXA recommended |
| Quality Of Life | Arthralgia and menopause-like symptoms affect QoL; symptomatic management helps |
Reference local guidelines such as eviQ and Cancer Australia when planning duration and monitoring protocols.
Alternatives Matrix
Comparison Considerations
| Drug | Mechanism | Typical PBS Status | Key Pros | Key Cons |
|---|---|---|---|---|
| Anastrozole | Non-steroidal aromatase inhibitor | Listed on PBS for similar indications (verify current status) | Comparable efficacy; alternate option if intolerance to letrozole | Arthralgia and bone loss risk similar |
| Exemestane | Steroidal aromatase inactivator | Often PBS-listed for postmenopausal HR+ disease | Option after intolerance to non-steroidal AIs | Steroidal effects; different side-effect profile |
| Tamoxifen | SERM | Longstanding PBS-listed option especially in premenopausal women | Different side-effect profile; bone-protective in some settings | Higher risk of hot flushes and thromboembolic events in some patients |
Pros And Cons Checklist For Shared Decision Making
- Consider efficacy for HR+ disease, tolerability, bone health effects, drug interactions and patient comorbidities.
- Review DEXA and lipid baseline when switching therapies and check PBS listing and authority requirements at prescribing time.
Common Questions From Australian Patients
Is it the same as Femara?
Yes. Femara is the principal brand of letrozole and Femara 2.5 mg tablets contain letrozole 2.5 mg.
How long will I be on it?
Commonly five years, sometimes extended based on clinical risk and prior tamoxifen exposure.
Can I take it with other medications?
Review your medication list with a pharmacist to check for interactions, especially strong CYP inducers or inhibitors.
- Pharmacy counselling scripts: acknowledge symptoms, advise on analgesia and exercise for joint pain, recommend baseline DEXA and calcium/vitamin D, and advise when to contact oncology.
Escalate care urgently for new or worsening bone pain, chest pain, sudden vision changes or severe hepatic symptoms.
- Definitions: DEXA — bone density scan; HR+ — hormone receptor positive; SERM — selective oestrogen receptor modulator; aromatase inhibitor — drug that lowers oestrogen production.
Price And Access Comparison Table
What To Include In A Patient-Facing Table
Recommend a clear table that lists source, typical out-of-pocket price range (leave prices to be updated locally), PBS subsidy status, lead time and notes about authority requirements.
Do not publish fixed prices in a national article; instruct pharmacists to update local pricing at the point of supply.
Access Checklist For Rural/Remote Patients
- Confirm local stock and pharmacy registration.
- Consider hospital supply bridging and telehealth e-prescription options.
- Arrange courier delivery and phone counselling where required.
- Document PBS concessions and authority approvals.
Advise patients to verify registration and licence of any online supplier and to avoid non‑regulated international purchases.
Registration, Regulation And Prescribing
Regulatory Status And Prescribing Governance
Letrozole/Femara is TGA-approved for its oncology indications in postmenopausal women.
Prescribers should follow TGA indications and PBS authority criteria when seeking subsidy.
Practical Regulatory Points For Pharmacists
- Check PBS item codes and authority requirements at time of supply and confirm patient eligibility for subsidy.
- Ensure correct repeats and maintain prescription records as required under Pharmacy Board guidelines.
- Report adverse events to the TGA Adverse Event Monitoring System and document counselling.
Storage And Handling
Household Storage Advice
Store below 30°C and protect from moisture and heat.
Keep letrozole in the original blister pack and avoid bathrooms or hot cars during Australian summers.
Store medicines out of reach of children and keep the original label for expiry and identification.
Pharmacy And Transport Handling
No cold chain is required; transport and storage at controlled room temperature under 30°C is sufficient.
When dispensing to remote addresses use insulated packaging if transit temperatures may exceed manufacturer recommendations.
- Patient counselling checklist: storage advice, missed-dose action, return unused tablets to pharmacy for safe disposal and check expiry dates before supply.
Guidelines For Proper Use And Pharmacist Counselling Style
Counselling Priorities And Patient Education
Use an evidence-based and empathetic approach when counselling patients starting letrozole.
Confirm the indication and explain the mechanism in simple terms and review absolute contraindications such as pre-menopausal status and pregnancy.
- Counselling checklist: dose and timing, missed dose instructions, likely side effects, monitoring plan (DEXA, lipids, LFTs), contraception requirements, and when to seek urgent care.
Integration With PBS And Clinician Teams
Coordinate with prescribers to align supply with PBS rules and ensure documentation of counselling and adverse drug reactions.
Provide written handouts or local guideline references such as eviQ and Cancer Australia and refer patients for non-pharmacological symptom management including exercise and bone-protective strategies.
Include a one-page patient summary with monitoring dates and contact details for quick reference at each supply.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Darwin | Northern Territory | 14-21 days |
| Gold Coast | Queensland | 14-21 days |
| Newcastle | New South Wales | 14-21 days |
| Wollongong | New South Wales | 14-21 days |
| Sunshine Coast | Queensland | 14-21 days |
| Geelong | Victoria | 14-21 days |
| Cairns | Queensland | 14-21 days |